Financial Toxicity in Patients With Resected Soft Tissue and Bone Sarcomas

M.D. Anderson Cancer Center100 enrolled

Overview

To learn about the financial stress patients undergoing surgery to treat orthopedic cancer experience because of the costs of cancer care, and to learn about the effects of financial stress on participants quality of life.

Measure the prevalence of financial toxicity and the severity of it in orthopaedic oncology patients undergoing surgical intervention using an objective, validated instrument. Secondary objectives include identifying socioeconomic and demographic risk factors for financial toxicity and evaluating clinicopathologic characteristics that may worsen financial stress in this population.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Bone Sarcomas Financial Toxicity

Interventions

data collectionOTHER

data collection from electronic health records

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Participants who are seen preoperatively at our institution before surgery for primary malignant bone tumor or primary malignant soft tissue tumor will be identified. * Adult orthopedic oncology patients. Stratified by diagnosis of primary malignant bone tumor and primary malignant soft tissue tumor. Exclusion Criteria • Non-English subjects will not be recruited. Subjects are required to be able to read/write in English.

Locations (1)

MD Anderson Cancer Center

Houston, Texas, United States

RECRUITING

Outcomes

Primary Outcomes

Questionnaires

Time frame: Through study completion; an average of 1 year

Central Contacts

Shalin S Patel, MD

CONTACT

713-792-6268 sspatel@mdanderson.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.